DNTH · XBRL financial data

Dianthus Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (DNTH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	2,826	6,235	2,036
Revenue from contracts with customers	—	—	—	2,826	6,235	2,036
Research and development	50,615	46,766	55,141	32,841	83,105	145,638
General and administrative	28,087	27,926	25,761	18,159	24,994	34,331
Total operating expenses	78,702	74,692	80,902	51,000	108,099	179,969
Operating income (loss)	(78,702)	(74,692)	(80,902)	(48,174)	(101,864)	(177,933)
Interest income	—	—	—	3,341	11,347	9,956
Other income (expense)	—	—	(52)	(60)	(554)	(974)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(74,936)	(71,136)	(76,462)	(43,555)	(84,969)	(162,337)
Earnings per share, basic USD per share	(1.71)	(1.29)	(1.29)	(8.45)	(2.55)	(4.20)
Earnings per share, diluted USD per share	(1.71)	(1.29)	(1.29)	(8.45)	(2.55)	(4.20)
Weighted average shares, basic thousands of shares	43,920	54,949	59,372	5,153	33,314	38,618
Weighted average shares, diluted thousands of shares	43,920	54,949	59,372	5,153	33,314	38,618

Fiscal years (DNTH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	58,152	131,650	57,626	132,325	22,792	51,087
Short-term investments	—	—	60,125	41,393	252,449	353,208
Marketable securities	90,683	45,276	54,415	—	—	—
Accounts receivable	—	—	4,700	294	807	52
Prepaid and other current assets	2,692	3,767	3,561	3,255	4,856	5,091
Total current assets	151,527	180,693	115,602	177,451	280,904	409,438
Property and equipment, net	8,312	7,461	6,095	185	194	296
Right-of-use asset	—	0	23,168	615	1,553	1,337
Total assets	161,619	189,934	146,645	179,405	374,008	530,922
Accounts payable	3,760	3,040	2,454	2,610	4,579	9,725
Accrued liabilities	7,670	7,823	8,271	6,504	13,074	19,452
Total current liabilities	11,430	10,863	14,549	9,631	18,452	30,732
Lease liability, non-current	—	0	26,138	168	1,171	1,019
Total liabilities	17,713	17,262	40,687	10,535	21,531	37,521
Accumulated deficit	(254,431)	(325,567)	(402,029)	(89,423)	(174,392)	(336,729)
Total stockholders' equity	143,906	172,672	105,958	168,870	352,477	493,401
Total liabilities and equity	161,619	189,934	146,645	179,405	374,008	530,922
Common shares outstanding (cover page) thousands of shares	48,556	58,799	60,640	29,347	32,125	44,471

Fiscal years (DNTH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(74,936)	(71,136)	(76,462)	(43,555)	(84,969)	(162,337)
Stock-based compensation	9,941	10,308	7,021	2,900	12,894	22,793
Depreciation and amortization	1,978	2,020	1,925	—	—	—
Net cash from operating activities	(64,023)	(59,531)	(67,090)	(36,861)	(78,180)	(129,060)
Purchases of property and equipment	400	1,264	314	—	—	—
Net cash from investing activities	(10,635)	43,428	(9,812)	20,253	(286,812)	(122,833)
Proceeds from issuing common stock	64,860	0	2,904	0	39,200	317
Net cash from financing activities	67,739	89,601	2,878	133,574	255,623	280,125
Net change in cash	(6,919)	73,498	(74,024)	116,966	(109,369)	28,232

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Dianthus Therapeutics	55,686	not reported	(50,334)*	56.3M	19.6 quarters	Q3 FY26 10-QSep 30, 2026
Stoke Therapeutics	107,271	11,255	(62,686)*	65.4M	5.2 quarters	Q3 FY26 10-QSep 30, 2026
Trevi Therapeutics	54,302	not reported	(17,429)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Amphastar Pharmaceuticals	223,614	183,903	51,324*	42.5M	—	Q2 FY26 10-QJun 30, 2026
Anaptysbio	133,826	27,488*	(26,640)*	29.9M	6.2 quarters	Q4 FY26 10-KTJun 30, 2026
Evolus	41,700	77,952	(1,933)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
Xencor	59,622	116,520	2,642*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Savara	41,800	not reported	(29,747)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Opko Health	384,036	65,414	(36,315)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.